×
About 7,463 results

ALLMedicine™ Familial Hypercholesterolemia Center

Research & Reviews  2,919 results

Factors Associated with Carotid Atherosclerosis and Achilles Tendon Thickness in Japane...
https://doi.org/10.5551/jat.62925
Journal of Atherosclerosis and Thrombosis; Ogura M, Harada-Shiba M et. al.

Jun 10th, 2021 - Familial hypercholesterolemia (FH) is characterized by high low-density lipoprotein (LDL) cholesterol levels, xanthomas including Achilles tendon thickening, and premature coronary artery disease (CAD). Carotid intima-media thickness (IMT) is a we...

Implementation of a Machine-Learning Algorithm in the Electronic Health Record for Targ...
https://doi.org/10.1161/CIRCOUTCOMES.120.007641
Circulation. Cardiovascular Quality and Outcomes; Sheth S, Lee P et. al.

Jun 10th, 2021 - Implementation of a Machine-Learning Algorithm in the Electronic Health Record for Targeted Screening for Familial Hypercholesterolemia: A Quality Improvement Study.|2021|Sheth S,Lee P,Bajaj A,Cuchel M,Hajj J,|

Measurement of Achilles Tendon Thickness is a Key for International Harmonization in Cl...
https://doi.org/10.5551/jat.ED180
Journal of Atherosclerosis and Thrombosis; Yokoyama S

Jun 7th, 2021 - Measurement of Achilles Tendon Thickness is a Key for International Harmonization in Clinical Diagnosis of Familial Hypercholesterolemia.|2021|Yokoyama S,|

Familial Hypercholesterolemia in the Arabian Gulf Region: Clinical results of the Gulf ...
https://doi.org/10.1371/journal.pone.0251560
PloS One; Alhabib KF, Al-Rasadi K et. al.

Jun 4th, 2021 - Familial hypercholesterolemia (FH) is a common autosomal dominant disorder that can result in premature atherosclerotic cardiovascular disease (ASCVD). Limited data are available worldwide about the prevalence and management of FH. Here, we aimed ...

Integrated analysis of microRNA and mRNA expression profiles in homozygous familial hyp...
https://doi.org/10.1016/j.ygeno.2021.05.036
Genomics Wu Y, Jiang L et. al.

May 30th, 2021 - Homozygous familial hypercholesterolemia (HoFH) is a rare, life-threatening genetic disorder characterized by an extremely elevated serum level of low-density lipoprotein cholesterol (LDL-C) and accelerated premature atherosclerotic cardiovascular...

see more →

Guidelines  9 results

Esperion Announces FDA Approval of NEXLETOL™ (bempedoic acid) Tablet, an Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine
https://esperion.gcs-web.com/node/11206/pdf

Feb 24th, 2020 - Esperion announced today that the U.S. Food and Drug Administration (FDA) approved NEXLETOL™ (bempedoic acid) tablet, an oral, once-daily, non-statin LDL-Cholesterol (LDL-C) lowering medicine. NEXLETOL is indicated as an adjunct to diet and maxima...

Canadian Cardiovascular Society Position Statement on Familial Hypercholesterolemia: Up...
https://doi.org/10.1016/j.cjca.2018.09.005
The Canadian Journal of Cardiology; Brunham LR, Ruel I et. al.

Dec 11th, 2018 - Familial hypercholesterolemia (FH) is the most common monogenic disorder causing premature atherosclerotic cardiovascular disease. It affects 1 in 250 individuals worldwide, and of the approximately 145,000 Canadians estimated to have FH, most are...

Screening for Lipid Disorders in Children and Adolescents: Clinical Summary
https://allmedx.com/USPSTFPDF/lipidscreening_ch-summary.pdf

Aug 2nd, 2016 - Figure. Screening for Lipid Disorders in Children and Adolescents: Clinical Summary Population Asymptomatic children and adolescents 20 years or younger Recommendation No recommendation. Grade: I (insufficient evidence) Ri...

Familial hypercholesterolemia.
https://www.ncbi.nlm.nih.gov/pubmed/24335046
Journal of Atherosclerosis and Thrombosis; Teramoto T, Sasaki J et. al.

Dec 17th, 2013 - Familial hypercholesterolemia.|2013|Teramoto T,Sasaki J,Ishibashi S,Birou S,Daida H,|diagnosis,etiology,prevention & control,diagnosis,etiology,prevention & control,diagnosis,prevention & control,

NEXLETOL™ (bempedoic acid) - A New Treatment Option‎
https://www.nexletolhcp.com/

Discover How NEXLETOL May Help Appropriate Patients. See Important Safety Information and Full Prescribing Information. Learn About New Treatment. FDA Approved. Get The Facts.

see more →

Drugs  363 results see all →

Clinicaltrials.gov  3,697 results

Factors Associated with Carotid Atherosclerosis and Achilles Tendon Thickness in Japane...
https://doi.org/10.5551/jat.62925
Journal of Atherosclerosis and Thrombosis; Ogura M, Harada-Shiba M et. al.

Jun 10th, 2021 - Familial hypercholesterolemia (FH) is characterized by high low-density lipoprotein (LDL) cholesterol levels, xanthomas including Achilles tendon thickening, and premature coronary artery disease (CAD). Carotid intima-media thickness (IMT) is a we...

Implementation of a Machine-Learning Algorithm in the Electronic Health Record for Targ...
https://doi.org/10.1161/CIRCOUTCOMES.120.007641
Circulation. Cardiovascular Quality and Outcomes; Sheth S, Lee P et. al.

Jun 10th, 2021 - Implementation of a Machine-Learning Algorithm in the Electronic Health Record for Targeted Screening for Familial Hypercholesterolemia: A Quality Improvement Study.|2021|Sheth S,Lee P,Bajaj A,Cuchel M,Hajj J,|

Measurement of Achilles Tendon Thickness is a Key for International Harmonization in Cl...
https://doi.org/10.5551/jat.ED180
Journal of Atherosclerosis and Thrombosis; Yokoyama S

Jun 7th, 2021 - Measurement of Achilles Tendon Thickness is a Key for International Harmonization in Clinical Diagnosis of Familial Hypercholesterolemia.|2021|Yokoyama S,|

Familial Hypercholesterolemia in the Arabian Gulf Region: Clinical results of the Gulf ...
https://doi.org/10.1371/journal.pone.0251560
PloS One; Alhabib KF, Al-Rasadi K et. al.

Jun 4th, 2021 - Familial hypercholesterolemia (FH) is a common autosomal dominant disorder that can result in premature atherosclerotic cardiovascular disease (ASCVD). Limited data are available worldwide about the prevalence and management of FH. Here, we aimed ...

Limited-Variant Screening Tests Often Miss Familial Hypercholesterolemia
https://www.medscape.com/viewarticle/952069

May 30th, 2021 - NEW YORK (Reuters Health) - Two-thirds of cases of familial hypercholesterolemia (FH) would be missed by relying on array-based genetic tests that screen for only a limited number of variants, according to a new study. "Negative findings on a limi...

see more →

News  471 results

Limited-Variant Screening Tests Often Miss Familial Hypercholesterolemia
https://www.medscape.com/viewarticle/952069

May 30th, 2021 - NEW YORK (Reuters Health) - Two-thirds of cases of familial hypercholesterolemia (FH) would be missed by relying on array-based genetic tests that screen for only a limited number of variants, according to a new study. "Negative findings on a limi...

An Expert's Guide to Managing Familial Hypercholesterolemia
https://www.medscape.com/viewarticle/948546

Apr 20th, 2021 - This transcript has been edited for clarity. Hi. I'm Seth Baum, a preventive cardiologist and clinical lipidologist in Boca Raton, Florida. I'm also the past president of the American Society for Preventive Cardiology and on the faculty at the Flo...

FDA Okays New Indication for Alirocumab in Homozygous FH
https://www.medscape.com/viewarticle/948580

Mar 31st, 2021 - The US Food and Drug Administration has approved alirocumab (Praluent, Regeneron Pharmaceuticals) injection as add-on therapy for adults with homozygous familial hypercholesterolemia, the agency announced. The proprotein convertase subtilisin/kexi...

Achilles Tendon Softness a New Tool to Diagnose FH
https://www.medscape.com/viewarticle/948460

Mar 30th, 2021 - Achilles tendon softness should be considered a new indicator of familial hypercholesterolemia, in addition to Achilles tendon thickness, researchers suggest. In a cross-sectional study that measured Achilles tendon thickness and elasticity (i. e ...

FDA Approves Orphan Drug Evinacumab-dgnb for Homozygous FH
https://www.medscape.com/viewarticle/945719

Feb 10th, 2021 - The US Food and Drug Administration has approved the fully human monoclonal antibody evinacumab-dgnb (Evkeeza, Regeneron Pharmaceuticals) for use on top of other cholesterol-modifying meds in patients aged 12 and older with homozygous familial hyp...

see more →

Patient Education  4 results see all →